U.S. markets closed

Compugen Ltd. (CGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9300-0.0333 (-3.46%)
At close: 04:00PM EDT
0.9399 +0.01 (+1.06%)
After hours: 04:23PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.9633
Bid0.9100 x 1000
Ask0.9502 x 1200
Day's Range0.8000 - 0.9729
52 Week Range0.5100 - 1.4900
Avg. Volume299,701
Market Cap87.583M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateNov 13, 2023 - Nov 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Compugen Ltd.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine, high European inflation or other geopolitical developments. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky, but diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • PR Newswire

    Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

    Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA.

  • Zacks

    Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?

    Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.

  • PR Newswire

    Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at from Monday, September 11, 2023, 7:00 AM ET for 30 days.